AG
AURA icon

Artal Group’s Aura Biosciences AURA Stock Holding History

Artal Group’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-410,000
Closed -$4.3M – 121
2022
Q4 		$4.3M Buy
+410,000
New +$5.22M 0.24% 67

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group's AURA Position: Q1 2023 in Review

Artal Group sold out of Aura Biosciences (AURA) in Q1 2023, closing a stake of 410,000 shares — an estimated $4.3M sold.

Artal Group first reported a position in AURA in Q4 2022 and held it in 1 quarter. The position peaked at $4.3M in Q4 2022. 57 funds tracked by Wall St. Rank hold AURA as of Q1 2023.

  • Artal Group reported no remaining Aura Biosciences position as of Q1 2023 after selling out during the quarter.
  • Artal Group sold 410,000 Aura Biosciences shares in Q1 2023, an estimated $4.3M.
  • Artal Group first reported a position in Aura Biosciences in Q4 2022 and held it in 1 quarter.
  • Artal Group's Aura Biosciences position peaked at $4.3M in Q4 2022.
  • 57 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.